11/19/2026 | Press release | Distributed by Public on 11/19/2026 09:20
DURHAM, N.C., November 19, 2026 - MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, has appointed Christy Mocny as Vice President of Quality. The appointment strengthens MedPharm's executive leadership and underscores the company's commitment to quality, regulatory compliance, and operational excellence.
Ms. Mocny brings more than 20 years of experience in pharmaceutical and medical device quality management, regulatory compliance, and global Quality Management Systems (QMS). She most recently served as Director of Corporate Quality, Global Audits & Compliance at Biogen, where she led global audit programs and initiatives focused on inspection readiness, quality systems, and enterprise-wide compliance.
In her new role, Ms. Mocny will lead MedPharm's Global Quality organization, overseeing quality systems, regulatory compliance, and audit and inspection readiness. She will also direct quality assurance operations supporting pharmaceutical development, analytical services, clinical trial materials, and commercial manufacturing.
"I am delighted to join MedPharm at such an exciting time for the business," said Christy Mocny, Vice President of Quality, MedPharm. "I look forward to building on the organization's strong quality foundations, advancing its systems and processes, and collaborating across the business to support continued growth and success."
"We are pleased to welcome Christy to MedPharm," said Bill Humphries, Chief Executive Officer, MedPharm. "Her extensive experience in quality management and regulatory compliance, together with her enterprise leadership approach, will be a valuable asset in support of MedPharm's accelerating rate of growth. Strong quality, and quality leadership at MedPharm is central to our success, and I am confident that Christy will help strengthen our organization and support its future growth."
- Ends -
About MedPharm
MedPharm provides end-to-end contract services for topical and transepithelial products, spanning early-phase research, formulation development, and in vitro testing through clinical and commercial manufacturing. Its 2024 merger with Tergus Pharma expanded the company's scale and capabilities, creating a differentiated CDMO offering that extends from drug development and formulation to large-batch commercial manufacturing and distribution.
For more than 25 years, MedPharm has helped reduce development risk through its unique, industry-leading in vitro testing and research biology models. The company is a global leader in product development for dermal/transdermal, lung and nasal, mucosal membrane, ungual, otic, and ophthalmic delivery. MedPharm operates in the United Kingdom and the United States, including a new 110,000 sq. ft. state-of-the-art manufacturing facility in Durham, North Carolina. For more information, visit medpharm.com or follow MedPharm on LinkedIn.
Media Contacts
Sadie Smith, Marketing and Events Coordinator
Email: [email protected]
Miles Fisher-Pollard, Orientation Marketing
Email: [email protected]